Labiotech.eu

More News! 1 Mar 2018

Just a Single Dose of this Drug Boosts the Survival of Heart Failure Patients

Berlin Cures’ drug fights off self-reactive antibodies that are associated with 80% of heart failure cases to improve heart function and patient survival. Berlin Cures was founded in 2014 to make use of research being carried out at Charité Medical University and the Max-Delbrueck-Center in Berlin. The biotech has achieved promising clinical data that suggests its first […]

March 1, 2018 - 3 minutesmins - By Alex Dale

Idorsia Actelion Spin Off Jean Paul Clozel CEO

News and Trends 1 Mar 2018

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Feb 2018

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with a checkpoint inhibitor to treat colorectal and pancreatic cancer. Notably, this is the third checkpoint inhibitor to be tested with Bavarian Nordic’s vaccine. A Phase I/II trial will evaluate the safety and efficacy of using Bavarian Nordic’s cancer vaccine CV301 in […]

February 28, 2018 - 3 minutesmins - By Alexander Burik

novo holdings antibiotic resistance fight 1

News and Trends 28 Feb 2018

Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance

Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance. Novo Holdings manages the assets of the Novo Nordisk Foundation, which invests money in companies that are working on scientific, humanitarian, and social projects. The company has launched a fund to develop new treatments for infections […]

February 28, 2018 - 3 minutesmins - By Alex Dale

More News! 28 Feb 2018

Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease?

Polish researchers tested a new variant of CRISPR/Cas9 that increases the gene-editing system’s precision in targeting specific DNA sequences, such as the gene responsible for Huntington’s disease. CRISPR/Cas9 offers a means of editing genes by essentially ‘cutting and pasting’ sequences of DNA. A group of researchers at the Institute of Bioorganic Chemistry in Poland has developed […]

February 28, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 28 Feb 2018

Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way

Researchers at the University of Cambridge believe that they have found the region of the brain that is responsible for pain relief, which should help future drug development efforts. Scientists at the University of Cambridge have identified the area of the brain that is responsible for pain relief, which could boost the development of alternative […]

February 28, 2018 - 4 minutesmins - By Alex Dale

News and Trends 28 Feb 2018

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time. A lack of financial incentive has put pharma off but biotechs are keen to step in and develop treatments and cures. Over 6,000 rare diseases affect up to 30 million people in the EU alone, which highlights […]

February 28, 2018 - 8 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy

Summit Therapeutics’ treatment for the devastating disease, Duchenne muscular dystrophy, reduces inflammation, which could protect muscle fibers from damage. Summit Therapeutics focuses on the development of treatments that can help patients suffering from diseases that currently lack options. The biotech has reported Phase II results for its drug for the genetic disease, Duchenne muscular dystrophy […]

February 27, 2018 - 3 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

Update: Deinove is About to Launch a Bacterial Anti-Aging Skincare Product

Update (27/2/2018): Deinove produced the first industrial batch of its carotenoid product and plans to launch the cosmetic skincare treatment at the In-Cosmetics tradeshow in Amsterdam this coming April. The news resulted in a soaring 57% increase of Deinove’s stock price. Originally published on 19/12/2017 Deinove has set the wheels in motion as it looks […]

February 27, 2018 - 2 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy

Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical company dedicated to women’s reproductive medicine, states that current Phase III results for the drug show an increase in pregnancy rate of 32 % after […]

February 27, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 27 Feb 2018

DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial

DBV Technologies’ candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin patch, Viaskin, as an immunotherapy for the treatment peanut, egg, and milk allergies. In a Phase II study, Viaskin Milk has desensitized children between the […]

February 27, 2018 - 3 minutesmins - By Alex Dale

News and Trends 26 Feb 2018

AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development

AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and efficiency of drug development. Pelago, a Karolinska Institute spin-off, studies the interactions between a drug and its target to make the drug development process faster and more efficient. The Cellular Thermal Shift Assay (CETSA) was developed by Pelago to examine the […]

February 26, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Just a Single Dose of this Drug Boosts the Survival of Heart Failure Patients

How is Actelion Spin-Off Idorsia Doing One Year Later?

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance

Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease?

Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy

Update: Deinove is About to Launch a Bacterial Anti-Aging Skincare Product

Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy

DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial

AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!